Dechert (Philadelphia)

Robert Rhoad

Dechert (Philadelphia)

Robert D. Rhoad is a partner with Dechert, based in the firm’s Philadelphia office, where he represents clients in intellectual property and complex commercial litigation, primarily involving patents and licensing disputes, but also involving trade secrets, unfair competition claims, and covenants not to compete. He handles cases involving a wide range of technology areas, including cases involving patent portfolios and other proprietary information relating to drug delivery systems, pharmaceutical products, medical devices, and computer hardware and software technologies. Mr. Rhoad has handled litigation and provided strategic patent advice for a diverse group of clients, including Endo Pharmaceuticals, Boston Scientific, Cardinal Health, Acer, Gateway, Hitachi, Pfizer, and other prominent life sciences and technology companies. He has handled many Markman hearings and trials, and has extensive experience litigating Hatch-Waxman Act ANDA infringement actions on behalf of branded pharmaceutical companies. Mr. Rhoad has tried cases in both state and federal court and has also successfully represented clients in arbitration, mediation, and other alternative dispute resolution proceedings. As a respected patent litigator, Mr. Rhoad is regularly invited to lecture at the annual Joint Patent Law Seminar, sponsored jointly by the Connecticut, New Jersey, New York, and Philadelphia Intellectual Property Law Associations, and other venues on issues of patent law, intellectual property protection, and trade secret law.

Linked authors

Dechert (New York)
Dechert (Washington)
Dechert (Paris)
Dechert (Moscow)
Dechert (Philadelphia)


349 Bulletin

Julia Chapman, George Gordon, Katherine A. Helm, Robert Rhoad, Andrew Figueiredo The US FTC issues a policy statement warning pharmaceuticals off improperly listing their drugs on the FDA’s "Orange Book" in order to delay the entry of generic rivals


Key Takeaways The FTC is focusing its attention on the listing of pharmaceutical patents in the FDA’s Orange Book. Patent listing may be the subject of FTC inquiry even absent infringement litigation enforcing the relevant patents. Companies should review existing Orange Book listings to (...)


Total visits

Number of readings per contribution

Number of contributions

Author's ranking
In number of contributions
In number of visits
In average number of visits
Send a message